Vanguard Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $236M | Buy |
10,263,815
+131,087
| +1% | +$4.31M | ﹤0.01% | 1464 |
|
|
2025
Q3 | $305M | Sell |
10,132,728
-80,694
| -0.8% | -$2.42M | ﹤0.01% | 1322 |
|
|
2025
Q2 | $371M | Buy |
10,213,422
+217,196
| +2% | +$7.83M | 0.01% | 1195 |
|
|
2025
Q1 | $362M | Sell |
9,996,226
-38,636
| -0.4% | -$1.61M | 0.01% | 1173 |
|
|
2024
Q4 | $422M | Buy |
10,034,862
+89,389
| +0.9% | +$4.43M | 0.01% | 1133 |
|
|
2024
Q3 | $552M | Buy |
9,945,473
+164,980
| +2% | +$8.4M | 0.01% | 980 |
|
|
2024
Q2 | $402M | Buy |
9,780,493
+1,080,486
| +12% | +$46.1M | 0.01% | 1095 |
|
|
2024
Q1 | $406M | Buy |
8,700,007
+26,575
| +0.3% | +$1.25M | 0.01% | 1113 |
|
|
2023
Q4 | $415M | Buy |
8,673,432
+1,440,264
| +20% | +$55.8M | 0.01% | 1085 |
|
|
2023
Q3 | $258M | Buy |
7,233,168
+214,666
| +3% | +$8.51M | 0.01% | 1303 |
|
|
2023
Q2 | $324M | Buy |
7,018,502
+265,175
| +4% | +$12.3M | 0.01% | 1191 |
|
|
2023
Q1 | $271M | Buy |
6,753,327
+379,097
| +6% | +$16.3M | 0.01% | 1283 |
|
|
2022
Q4 | $295M | Buy |
6,374,230
+212,364
| +3% | +$8.35M | 0.01% | 1194 |
|
|
2022
Q3 | $255M | Buy |
6,161,866
+27,722
| +0.5% | +$1.42M | 0.01% | 1247 |
|
|
2022
Q2 | $366M | Buy |
6,134,144
+170,770
| +3% | +$10.5M | 0.01% | 1046 |
|
|
2022
Q1 | $433M | Buy |
5,963,374
+42,806
| +0.7% | +$2.98M | 0.01% | 1064 |
|
|
2021
Q4 | $498M | Buy |
5,920,568
+45,737
| +0.8% | +$3.72M | 0.01% | 1001 |
|
|
2021
Q3 | $530M | Buy |
5,874,831
+208,494
| +4% | +$18.8M | 0.01% | 940 |
|
|
2021
Q2 | $540M | Sell |
5,666,337
-223,128
| -4% | -$23.2M | 0.01% | 948 |
|
|
2021
Q1 | $671M | Buy |
5,889,465
+239,080
| +4% | +$32.5M | 0.02% | 789 |
|
|
2020
Q4 | $782M | Buy |
5,650,385
+292,550
| +5% | +$34.7M | 0.02% | 676 |
|
|
2020
Q3 | $440M | Buy |
5,357,835
+219,578
| +4% | +$18.2M | 0.01% | 831 |
|
|
2020
Q2 | $402M | Buy |
5,138,257
+169,418
| +3% | +$11.2M | 0.01% | 858 |
|
|
2020
Q1 | $221M | Buy |
4,968,839
+115,680
| +2% | +$6.01M | 0.01% | 1076 |
|
|
2019
Q4 | $207M | Sell |
4,853,159
-219,766
| -4% | -$9.07M | 0.01% | 1369 |
|
|
2019
Q3 | $217M | Buy |
5,072,925
+67,053
| +1% | +$3.64M | 0.01% | 1283 |
|
|
2019
Q2 | $318M | Buy |
5,005,872
+112,101
| +2% | +$7.14M | 0.01% | 1064 |
|
|
2019
Q1 | $339M | Buy |
4,893,771
+731,991
| +18% | +$41.8M | 0.01% | 1008 |
|
|
2018
Q4 | $181M | Buy |
4,161,780
+109,757
| +3% | +$6M | 0.01% | 1302 |
|
|
2018
Q3 | $309M | Sell |
4,052,023
-23,225
| -0.6% | -$1.89M | 0.01% | 1095 |
|
|
2018
Q2 | $313M | Buy |
4,075,248
+129,215
| +3% | +$8.35M | 0.01% | 1051 |
|
|
2018
Q1 | $201M | Buy |
3,946,033
+779,568
| +25% | +$39.3M | 0.01% | 1289 |
|
|
2017
Q4 | $147M | Buy |
3,166,465
+25,447
| +0.8% | +$1.25M | 0.01% | 1495 |
|
|
2017
Q3 | $167M | Buy |
3,141,018
+10,745
| +0.3% | +$637K | 0.01% | 1396 |
|
|
2017
Q2 | $194M | Buy |
3,130,273
+135,335
| +5% | +$8.15M | 0.01% | 1246 |
|
|
2017
Q1 | $203M | Buy |
2,994,938
+161,622
| +6% | +$12.3M | 0.01% | 1219 |
|
|
2016
Q4 | $199M | Buy |
2,833,316
+170,656
| +6% | +$12.1M | 0.01% | 1172 |
|
|
2016
Q3 | $189M | Buy |
2,662,660
+72,942
| +3% | +$4.66M | 0.01% | 1148 |
|
|
2016
Q2 | $127M | Buy |
2,589,718
+120,999
| +5% | +$7.83M | 0.01% | 1344 |
|
|
2016
Q1 | $156M | Buy |
2,468,719
+75,132
| +3% | +$4.92M | 0.01% | 1172 |
|
|
2015
Q4 | $269M | Buy |
2,393,587
+275,497
| +13% | +$27.5M | 0.02% | 840 |
|
|
2015
Q3 | $204M | Buy |
2,118,090
+378,866
| +22% | +$43.4M | 0.01% | 986 |
|
|
2015
Q2 | $178M | Buy |
1,739,224
+143,998
| +9% | +$11.2M | 0.01% | 1134 |
|
|
2015
Q1 | $99M | Buy |
1,595,226
+285,974
| +22% | +$15.9M | 0.01% | 1507 |
|
|
2014
Q4 | $57.5M | Buy |
1,309,252
+218,290
| +20% | +$10M | ﹤0.01% | 1764 |
|
|
2014
Q3 | $61.7M | Buy |
1,090,962
+818,049
| +300% | +$41.2M | ﹤0.01% | 1684 |
|
|
2014
Q2 | $12.3M | Buy |
272,913
+59,026
| +28% | +$2.43M | ﹤0.01% | 2420 |
|
|
2014
Q1 | $10.5M | Buy |
+213,887
| New | +$11M | ﹤0.01% | 2468 |
|
Other funds holding RARE
RI
BBA
SCM
Vanguard Group's RARE Position: Q4 2025 in Review
Vanguard Group increased its Ultragenyx Pharmaceutical (RARE) stake by 1.3% in Q4 2025, buying an estimated $4.31M and bringing the position to 10,263,815 shares worth $236M. The position accounts for ﹤0.01% of the portfolio, ranked #1464.
Vanguard Group first reported a position in RARE in Q1 2014 and has held it in 48 quarters since. The position peaked at $782M in Q4 2020. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.
- Vanguard Group held 10,263,815 shares of Ultragenyx Pharmaceutical worth $236M as of Q4 2025.
- Vanguard Group bought 131,087 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $4.31M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1464 holding.
- Vanguard Group first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 48 quarters since.
- Vanguard Group's Ultragenyx Pharmaceutical position peaked at $782M in Q4 2020.
- 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.